The Levitronix PediVAS is an extracorporeal magnetically levitated pediatric ventricular assist system with an optimal flow rate range of 0.3-1.5 L/min. The system is being tested in preclinical studies to assess hemodynamic performance and biocompatibility. The PediVAS was implanted in nine ovines for 30 days using either commercially available cannulae (n ‫؍‬ 3) or customized Levitronix cannulae (n ‫؍‬ 6). Blood biocompatibility in terms of circulating activated platelets was measured by flow cytometric assays to detect P-selectin. Platelet activation was further examined after exogenous agonist stimulation. Platelet activation increased after surgery and eventually returned to baseline in animal studies where minimal kidney infarcts were observed. Platelet activation remained elevated for the duration of the study in animals where a moderate number of kidney infarcts with or without thrombotic deposition in the cannulae were observed. When platelet activation did return to baseline, platelets appropriately responded to agonist stimulation, signifying conserved platelet function after PediVAS implant. Platelet activation returned to baseline in the majority of studies, representing a promising biocompatibility result for the Levitronix PediVAS. ASAIO Journal 2011; 57:516 -521.
Available options for mechanical circulatory support in the pediatric population have lagged far behind the options available to adults. [1] [2] [3] Despite limited options for children and especially small children, the successful use of ventricular assist devices (VADs) in pediatric heart failure is on the rise, with VAD recipients achieving a 77% survival rate to heart transplant. 1, 4 Infants listed for heart transplant have the highest waiting list mortality in all solid organ transplantation. 5 Clearly, this patient population would greatly benefit from the increased availability of support options while awaiting heart transplantation. 4 There is also an unmet need for pediatricsized pumps to provide short-term as a bridge to decision (bridge to a longer term support device or myocardial recovery). 6 The Levitronix PediVAS (Figure 1 ) is a magnetically levitated extracorporeal pump similar in design to the Levitronix CentriMag, an adult pump that has been implanted in more than 6000 patients worldwide. The CentriMag has been successfully applied as a bridge to decision as a left, right or bi-ventricular assist device and further has been utilized in extracorporeal membrane oxygenation (ECMO) circuits. [7] [8] [9] The PediVAS can provide 0.3-1.5 L/min of flow for up to 30 days and has been implanted in more than 500 children worldwide. 6 Of note, the PediVAS has recently been implanted in the United States on a compassionate use basis. Its ability to generate "lower" flow rates (Ͻ2 L/min) is important as it is estimated that the largest cohort of pediatric patients that would benefit from VADs is less than one year of age. 4, 5, 10 The PediVAS is currently undergoing final preclinical studies in preparation for clinical trial in the United States.
Thrombosis and thromboembolism remain as significant biological complications in patients implanted with VADs. [11] [12] [13] [14] Given the significant morbidity caused by these complications, comprehensive preclinical assessment of platelet activation and thrombosis is merited in devices under development for the pediatric population. Recently, in the ovine model, pediatric VAD biocompatibility has been characterized with flow cytometric assays that could detect platelet activation. 6, [15] [16] [17] In several of these studies, the assays demonstrated sensitivity in responding to animal and pump complications. 16, 17 Ovine sham studies were also previously performed to mimic the surgical insult for a VAD implant and demonstrated that the effects of surgery on platelet activation dissipate within approximately 2 weeks. 17 These studies indicated that further platelet activation above that of the sham surgeries or after surgically induced platelet activation has dissipated could be attributed to the conditions of circulatory support under investigation. The objective of this report was to characterize the blood biocompatibility of the Levitronix PediVAS with commercially available cannulae or customized Levitronix cannulae (Figure 2 ) in terms of circulating activated platelets and further to validate the safety and efficacy of the customized cannulae for its pediatric indication in the juvenile ovine model.
Materials and Methods

Blood Collection
All animal studies were performed in compliance with the University of Pittsburgh Institutional Animal Care and Use Committee and National Institutes of Health (NIH) guidelines for the care and the use of laboratory animals. Preoperative blood was drawn via jugular venipuncture using an 18-gauge 1.5-in needle with syringe, discarding the first 3 ml. Blood (2.7 ml) was added to monovettes containing 0.3 ml of 0.106 M trisodium citrate (Sarstedt, Newton, NC). At least two preoperative samples were collected and results averaged to obtain the preoperative platelet activation data point (postoperative day 0).
Postoperative samples were collected from the carotid arterial line inserted during surgery. Samples were obtained on postoperative days 1, 2, and 3 and then twice weekly for the duration of each surgical study. Samples were collected by withdrawing 20 ml of blood to clear the catheter, then the sample volume (2.7 ml), and then reinfusing the initial 20 ml of blood.
Assessment of Platelet Activation
Platelet activation was assessed pre-and postsurgery with samples from each animal implanted with the Levitronix PediVAS. Platelet activation was also assessed after stimulation using platelet activating factor (PAF; Calbiochem, San Diego, CA).
Blood (5 l) was transferred from monovette tubes into 12 ϫ 75 mm polystyrene tubes with 5 l of CAPP2A (7.5 g/ml; Veterinary Medical Research and Development VMRD, Pullman, WA), 5 l of goat anti-mouse IgG-phycoerythrin (60 g/ml; Invitrogen, Carlsbad, CA), and 35 l of Tyrode's buffer (Electron Microscopy Services, Hatfield, PA) with 1% bovine serum albumin (BSA) and 0.106 M sodium citrate and incubated for 20 minutes. PAF-stimulated samples were prepared as above using 25 l of Tyrode's buffer with BSA, 5 l of 100 M PAF, and 5 l of 20 mM glycine-proline-arginine-proline (GPRP for inhibition of fibrin polymerization, AnaSpec, San Jose, CA).
Samples were then washed with 1 ml of Tyrode's buffer with 1% BSA and 0.106 M sodium citrate (washing buffer) and mixed. Samples were then centrifuged for 10 minutes at 132g. The supernatant was removed and the pellet resuspended. IgG1-Alexa Fluor 488 (isotype control; 5 l of 25 g/ml; MCA928A488, AbD Serotec), MCA2418-Alexa Fluor 488 (5 l of 25 g/ml; MCA2418-A488), or MCA2419-Alexa Fluor 488 (5 l of 25 g/ml; anti-human CD62P-clone Psel.KO.2.7, AbD Serotec) were then added to tubes and incubated for 20 minutes. Samples were then mixed with 1 ml of washing buffer and centrifuged at 132g. After removal of the supernatant, samples were fixed with 1% paraformaldehyde. Flow cytometric analysis was performed as previously described. 15 
Levitronix Custom Cannulae
The Levitronix custom cannulae are composed of a urethane body with an integral stainless steel-reinforced thin wall that is Dacron-wrapped to promote tissue ingrowth. The inflow cannula has a custom tip design and the outflow cannula incorporates an integrally attached collagen-coated woven graft on the cannula tip. Computational fluid dynamics were performed using the Levitronix custom cannulae and indicated smooth transport of blood along all cannula surfaces with no areas of stasis and minimal high shear regions that would indicate a risk for hemolysis (data not shown).
Implant Procedure
Nine healthy ovines (20 -30 kg) were implanted with the Levitronix PediVAS. Anesthesia was induced with ketamine and maintained with inhalation isoflurane. An arterial line for pressure measurement was placed in the left carotid artery along with a venous line for pharmacologic and fluid administration into the jugular vein. The heart was exposed via a left thoracotomy through the fourth intercostal space. The 6-mm custom Levitronix inflow cannula was communicated with the left ventricle through a stab incision to the heart and secured with a felt-coated sewing ring fixed on the apex of the heart with pledgeted sutures. In the studies utilizing the commercially available 16-Fr Medtronic inflow cannula (Medtronic, Minneapolis, MN; Model CB67316), the cannula was inserted into the left atrium using two pledgeted purse string sutures. The inflow cannulae were then connected to primed medical grade Tygon tubing (inner diameter, 0.25 in) that was attached to the pump inflow connector.
After bolus administration of heparin (150 U/kg), the outflow cannula [12 Fr, Medtronic (Model CB77112) or the 6-mm custom Levitronix outflow cannula] was sewn onto the descending aorta and the cannula was then fixed unto medical grade Tygon tubing (inner diameter, 0.25 in) directly connected to the pump outflow connector. An ultrasonic flow probe was connected onto the outflow tubing for measurement of PediVAS blood flow. Pressure was not measured near the PediVAS pump head, preventing the assessment of cannula resistance. Approximate tubing lengths for inflow and outflow Tygon tubing were 75 and 110 cm, respectively. The pump was started and operated at a flow range (0.5-1.5 L/min).
Bupivacaine hydrochloride (Hospira Inc., Lake Forest, IL) was used in the intercostal muscles, and flunixin meglumine (Phoenix Pharmaceutical, Inc., St. Joseph, MO; 25 mg intravenously) was used for analgesia. After closure of the chest, each animal was allowed to recover from anesthesia and spontaneously ventilate. No heparin was administered for 24 -48 hours after surgery. Heparin was then administered to maintain the activated clotting time between 180 and 200 seconds. Intravenous coumadin (Bristol-Myers Squibb; Princeton, NJ) was used to maintain the international normalized ratio (INR) in the range of 2.0 -3.0. Implanted animals were followed for 30 days. At the end of each implant, a necropsy was performed which included an evaluation of renal infarcts. Each kidney was examined and photographed, and renal infarcts were quantified. The kidney was further dissected to examine the level of penetration of any observed infarcts. The cannula, Tygon tubing, and pump surfaces were also photographed and evaluated for the presence of thrombus deposition. A summary of necropsy findings and the corresponding PediVAS flow rate for each implant is shown in Table 1 .
Statistical Analysis
All data are presented as mean with SD. Statistical analyses were performed using SPSS 12.0.1 (SPSS, Chicago, IL). One-way analysis of variance with repeated measures (Bonferroni post hoc test) was used to compare the means of platelet activation at different time points for each cannula cohort. One-way analysis of variance was used to compare previously collected preoperative platelet activation data from a jugular venous catheter to postoperative platelet activation data from days 21, 24, 28, and 30 in the nine animals implanted with the Levitronix PediVAS. 17 Significance was considered to exist for p Ͻ 0.05.
Results
In Vivo PediVAS Studies Using Commercially Available Cannulae
The Levitronix PediVAS system is illustrated in Figure 1A and a close up of the PediVAS pump head is illustrated in Figure 1B . The Levitronix customized inflow cannula and outflow cannula set is shown in Figure 2 . Figure 3 shows platelet activation after implantation of the PediVAS system with commercially available cannula. Platelet activation rises after surgery and by postoperative day 10 had returned to baseline. Stimulation with PAF induced a considerable increase in platelet activation compared with platelet activation in blood that was not stimulated (upper curve).
In Vivo PediVAS Studies Using Custom Cannulae
Platelet activation after implantation of the Levitronix Pedi-VAS using the custom cannulae in the subset of animals that had Յ4 kidney infarcts is depicted in Figure 4 . Platelet activation in these animals increased after surgery but decreased to baseline values by the third postoperative week. Platelet activation after stimulation was substantially higher than platelet activation before stimulation (upper curve). Platelet activation in the subset of animals that had Ͼ4 kidney infarcts with or without thrombus deposition in the cannulae is illustrated in Figure 3 . Platelet activation after Levitronix PediVAS implant using the commercially available Medtronic cannula before (lower curve) and after (upper curve) stimulation with 10 M PAF in implants (n ϭ 3). Figure 5 . Platelet activation in these animals rose after surgery and remained elevated throughout the study. In these studies, platelets demonstrated a limited ability to further respond to exogenous platelet stimulus (upper curve).
Discussion
The Levitronix PediVAS was designed without bearings, seals, and with large fluid gaps to promote biocompatibility. 6, 18 The computational fluid dynamics modeling of the blood pump conducted by Zhang et al. 18 also showed no areas of stasis, and the majority of the flow field had areas of low shear (Ͻ100 Pa) which suggested the potential for promising blood biocompatibility. Low hemolysis levels were demonstrated during initial in vitro and in vivo studies. 6, 18 Platelet activation was studied during these initial in vivo studies; however, the assays used were of limited sensitivity and the p-selectin assay use was limited (n ϭ 2), making it difficult to make substantive conclusions about platelet biocompatibility.
High preoperative platelet activation has been reported several times in the literature before preclinical pediatric VAD implantation in ovines and has been attributed to animal stress during blood collection. 6, 16, 17 The placement of a jugular venous catheter was previously shown to reduce preoperative platelet activation to a mean of 11% Ϯ 6%; however, we were not able to place catheters preoperatively in the current study. 17 The use of direct venipuncture in this study could generally explain the higher levels of platelet activation observed at the preoperative time point. As latter blood was obtained through a vascular catheter, there could be a bias toward more artifactual activation in the preoperative blood sample. Platelet activation after implantion of the PediVAS (Figures 3-5) was elevated in the early postoperative period as expected. As a result, the preoperative platelet activation artifact makes it more challenging to assess postoperative platelet activation as it appears that platelet activation does not rise after surgery. However, without the putative preoperative artifact, a postoperative rise in platelet activation would be anticipated.
Recently ovine sham surgical studies were performed which mimic the VAD implantation procedure. In these studies, platelet activation due to the surgical insult rose and returned to baseline levels in approximately 2 weeks. 17 As the implanted animals are otherwise healthy, ongoing platelet activation after 2 weeks can be attributed to the conditions of PediVAS support. Since the PediVAS is an extracorporeal device, it is also important to note that deployment of this device requires the use of medical grade Tygon tubing along with connectors that may impact biocompatibility. Given the surface area and length of the Tygon tubing in contact with blood, its impact on biocompatibility may not be negligible.
Cannula design is an essential component of VAD development, and cannula design parameters can have a significant impact on hemodynamic performance and biocompatibility. 19, 20 As a result, it is essential to evaluate the hemodynamic and biocompatibility performance of the PediVAS along with the customized cannula. Platelet activation in the commercial cannula studies (Figure 3) and the custom cannula cohort with Յ4 kidney infarcts was elevated perioperatively but quickly returned to baseline within 2-3 weeks, a temporal response that was similar to that of the sham surgical studies. 17 The low level of activation was accompanied by an ability of the platelets to respond to agonist stimulation, demonstrating that the low level of activation after the perioperative period was indicative of conserved platelet function.
Postoperative platelet activation in Figures 3 and 4 demonstrated a downward trend toward a preoperative platelet activation level. However, because preoperative platelet activation was elevated, a comparison of the platelet activation to the preoperative baseline of 11% obtained in a previous report by Johnson et al. 17 might be a more relevant data point for comparison. Platelet activation at the end of the study in the commercial cannula cohort and Levitronix custom cannula cohort with Յ4 kidney infarcts were comparable to the baseline of 11%. Given the relatively small group sizes, this study was not adequately powered to determine statistical differences in temporal platelet activation for each cannula cohort.
Platelet activation ( Figure 5 ) was higher in the custom cannula cohort where there were a greater number of kidney infarcts with or without thrombotic deposition in the cannulae at necropsy compared with results from Figure 4 . Furthermore, there was less activation possible after stimulation in the moderate infarct group due to the higher initial platelet activation. These results suggest a potential relationship between the level of ongoing platelet activation and the presence of kidney infarcts. The PediVAS flow rate is a variable that might explain the differences in platelet activation and necropsy data from the implants; however, the flow rates for the cannula cohorts were not statistically different.
In the custom cannula cohort ( Figure 5 ) where moderate kidney infarcts were observed, serum chemistry values (creatinine) for kidney function were normal, despite the thrombotic injury. Creatinine, however, is thought to be a poor indicator of kidney injury. 21 More sensitive biomarkers such as neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 have been shown to predict acute kidney injury in humans. 22 However, these biomarkers are not available in the ovine model in that there is inadequate cross-reactivity. Markers of hemostatic activation such as D-dimer, platelet factor 4, and other proteins for which there are commercially available enzyme-linked immunoassays also do not currently have cross-reactivity in the ovine model. Previous in vivo ovine studies demonstrated that fibrinogen and platelet count had a transient increase after surgery, suggesting that these indices were responsive to immediate surgical effects. 6, 16, 17 The general paucity of sensitive assays in the ovine model illustrates the potential utility of flow cytometric platelet activation assays in the armamentarium of biocompatibility assessment.
It would be most desirable to have a device proceeding to clinical trial with a minimal level of platelet activation and kidney infarcts observed in preclinical studies. However, such a design goal may be unrealistic during preclinical studies, and the presence of some platelet activation and presence of renal infarcts does not preclude clinical success. Preclinical studies of the HeartMate II VAD implanted in the bovine model showed that platelet activation was persistently elevated (35%-55%) after the surgical effects had dissipated. 23 Renal infarcts were also observed in these preclinical implants. Of these, implants with uncomplicated postoperative courses were generally observed to have less than five renal infarcts at necropsy. This study provided the rationale to assign a cutoff of four infarcts to assess the Levitronix implants described in this study.
Clinically, the HeartMate II has been approved by the Food and Drug Administration and successfully implanted in thousands of patients; however, stroke rates have been reported to occur in 8%-18% of patients, not including other cases of device thrombosis. 24 -26 Although the HeartMate II has been immensely successful, the stroke rates are of concern and can still be improved. The promising clinical results with the HeartMate II despite persistent platelet activation and some renal infarcts in preclinical animal models suggest that further reduction in observed preclinical platelet activation after the effects of surgery have dissipated could potentially lead to lower stroke rates in clinical practice, and this should be the focus during preclinical VAD design.
The temporal course of platelet activation (Figure 3 ) in the commercially available cannula cohort was of shorter duration and amplitude than that observed in the Levitronix custom cannula studies with Յ4 kidney infarcts (Figure 4) . This might suggest that the commercial cannula has greater potential for more promising biocompatibility for the PediVAS than the custom cannulae. Significant differences in the two cannula cohorts that might have impacted platelet activation results include the difference in inflow cannulation site and the cannula blood contacting surfaces; the commercial cannula had a Carmeda BioActive coating.
The moderate number of kidney infarcts and thrombotic deposition observed in some of the custom cannula cohort suggest that some further investigation may be prudent to ensure the safe biocompatibility of the PediVAS in children with this cannula set. Such investigation might address ways to apply a biomimetic coating to the pump, cannulae, or tubing or to investigate ways to reduce the amount of tubing used in PediVAS implants to reduce the blood contacting surface area. In summary, the PediVAS was successfully implanted, met hemodynamic requirements, and demonstrated promising biocompatibility with both cannula sets. Platelet activation was elevated to a greater extent when there were a greater number of kidney infarcts and thrombotic deposition in the cannula.
Conclusions
The Levitronix PediVAS was successfully implanted in nine animals and met its hemodynamic goals in successfully pumping ovine blood in the desired flow range of 0.5-1.5 L/min. Platelet activation assays generally trended with the presence of kidney infarcts. These assays also appeared to be more sensitive than traditional clinical markers of renal function with respect to the presence of renal infarcts. Overall, in the majority of studies, platelet activation returned to near baseline levels by 3 weeks which is an encouraging biocompatibility result during preclinical trials.
